RxDoctor Payments Data

Marc Weinberg

Nephrology · Providence, RINPI 1558364604

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 142 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $976 and has fallen 92.4% since, to $74 in 2025.

$2,587in general payments, 2019–2025

Across 142 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arbor Pharmaceuticals, Inc.$286
  • Novartis$275
  • Johnson & Johnson$255
  • Teva Pharmaceuticals USA, Inc.$248
  • Bayer$241
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$232
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,583100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,587 in reported general payments places this provider in the 70th percentile of 45 nephrology providers in Rhode Island.

See all nephrology providers in Rhode Island

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$39,473
MounjaroTirzepatide14$31,483
Repatha SureclickEvolocumab20$22,554
XareltoRivaroxaban22$20,190
EliquisApixaban21$13,287
Candesartan Cilexetil30$4,374
Rosuvastatin Calcium99$2,041
Omega-3 Acid Ethyl Esters30$1,605
Olmesartan Medoxomil23$1,266
Propranolol Hcl ErPropranolol Hcl13$541
Omeprazole38$513
Amlodipine Besylate42$476
Ezetimibe14$408
Tamsulosin Hcl16$368
Escitalopram Oxalate24$360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$77$39,47326 claims
Lilly USA, LLCMounjaro$128$31,48314 claims
Johnson & JohnsonXarelto$255$20,19022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 45 nephrology providers in Rhode Island.

Other nephrology in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →